TriSalus Life Sciences Appoints Industry Expert Sean Murphy to Board of Directors
DENVER & CHICAGO--(BUSINESS WIRE)-- TriSalus Life Sciences®, an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated, today announced the appointment of Sean Murphy to its Board of Directors.
Murphy brings to TriSalus decades of experience commercializing biopharmaceutical, medical device and diagnostic products. Over the span of his 40+ year career, Murphy has held various executive leadership roles at several global health care companies, including head of corporate M&A and business development at Abbott Laboratories/AbbVie. Most recently, Murphy served as the executive vice president of Malin PLC, a company he co-founded, where he led oversight of a large portfolio of highly innovative life sciences companies. Prior to that, Sean advised Fortune 500 biopharmaceutical companies on mergers, acquisitions, licensing and capital market transactions as a senior advisor at Evercore Partners.
“We are excited to have Sean, an industry titan with decades of experience, join the Board of TriSalus Life Sciences. Sean’s expertise in business development and experience advising health care companies to build strong, profitable brands is unparalleled and we are fortunate to benefit from his knowledge and creative thinking,” said Mary Szela, chief executive officer and president of TriSalus Life Sciences. “His passion for cutting edge solutions that improve patient care will be immensely valuable to our company as we work to rapidly bring potentially transformative treatments to patients living with liver and pancreatic cancers.”
“It’s an honor to be appointed to the TriSalus Board of Directors and leverage my industry experience to help make a positive change in the lives of patients dealing with such hard-to-treat cancers,” said Sean Murphy. “I look forward to strengthening and building upon TriSalus' organ-specific platform, which has the potential to overcome the key barriers that limit treatment success for liver and pancreatic cancers.”
Murphy currently serves on the boards of Radius Health, a publicly traded biopharmaceutical company focused on developing and commercializing innovative endocrine therapeutics; Xenex Corporation, a privately held UV technology-based company focused on disinfection strategies and solutions; Immucor, a privately held blood and tissue diagnostics company; and Prenosis, a privately held company focused on precision diagnostics in acute care using artificial intelligence. Murphy received a bachelor’s degree in business administration from Western Illinois University and a master’s degree in finance from University of Illinois-Champaign. He is also a certified public accountant licensed in the state of Illinois.
TriSalus recently announced a significant milestone, with its first patient enrolled in the Pressure Enabled Regional Immuno-Oncology (PERIO)-01 clinical study evaluating the administration of an investigational toll-like receptor 9 (TLR9) agonist in adults with uveal melanoma liver metastases. This study is the first program evaluating TriSalus’ platform aimed at improving patient outcomes in liver and pancreatic cancer by delivering SD-101 directly to the site of disease via proprietary drug delivery technology. To learn more about TriSalus’ ongoing efforts to activate the patient’s own immune cells within the liver and overcome the specific immunological pathways in the liver that cause treatment failure, visit www.trisaluslifesci.com.
About TriSalus Life Sciences
TriSalus Life Sciences is an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated. TriSalus' organ-specific platform integrates therapeutics and innovative device technology to address the dual challenges of immunosuppression and pressure, two of the most significant barriers that limit the effectiveness of current treatments in liver and pancreatic cancer.
The company's lead investigational compound, SD-101, aims to reactivate the immune system within these organs to fight cancer and enhance the effectiveness of other immunotherapy cancer treatments designed to limit cancer growth (e.g., checkpoint inhibitors, CAR T-cell therapy). The device, which leverages TriSalus’ FDA-cleared, Pressure-Enabled Drug Delivery™ (PEDD™) technology, is intended to open up collapsed blood vessels, overcoming pressure inside the tumor to deliver medicine deep inside. While meaningful progress in these difficult-to-treat diseases will not be easy, TriSalus is seeking to transform the battle with liver and pancreatic cancer through deep science, technology innovation, and an absolute focus on the patient. To learn more, visit us at www.trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005098/en/
Source: TriSalus Life Sciences
View this news release online at: